News Conference News ISET 2023 BioMimics 3D Stent Holds Up Well at 3 Years in Complex PAD Lesions Caitlin E. Cox January 20, 2023
News Conference News VIVA 2021 EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions L.A. McKeown October 12, 2021
News Industry News Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD August 07, 2019
News Daily News DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms Caitlin E. Cox July 11, 2019
News Conference News ISET 2019 Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis Caitlin E. Cox January 30, 2019
News Daily News Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies L.A. McKeown January 23, 2019
News Conference News TCT 2018 Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released Todd Neale September 24, 2018
News Conference News TCT 2018 IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease Todd Neale September 22, 2018
News Industry News Boston Scientific Receives CE Mark For Eluvia™ Drug-Eluting Vascular Stent and Announces Initiation of New Clinical Trial February 21, 2016
News Industry News Boston Scientific Announces FDA Approval of Innova™ Vascular Self-Expanding Stent System August 19, 2015